Managing Atrial Fibrillation (New Antiarrhythmics and New Anticoagulants): Do They Represent Improvements over Previously Available Therapy?

Moderator:

Discussants:

  • Summary:

    Dr. James Reiffel from Columbia University moderated the topic "Managing Atrial Fibrillation (New Antiarrhythmics and New Anticoagulants): Do They Represent Improvements over Previously Available Therapy?" with Drs. Peter Kowey from Jefferson Medical College, and Gerald Naccarelli from the Penn State University College of Medicine participating.

    The discussion focused primarily on:
    (1) the rhythm control approach,
    (2) American and European guidelines,
    (3) details of the ATHENA trial,
    (4) cardioversion with "pill in a pocket" therapy,
    (5) the ACT and AVRO trials in Europe studying vernakalant,
    (6) preclinical data showing efficacy of dronedarone and ranolazine combination therapy,
    (7) ablation therapy,
    (8) anti-coagulation therapy, including the ROCKET-AF study, and new drug therapies, and
    (9) side effects of drug therapy.
    (Med Roundtable Cardiovasc Ed. 2011;2(1):57-64) ©2011 FoxP2 Media, LLC

You are not authorized to access this content.

You are not authorized to access this content.
You are not authorized to access this content.
Please subscribe to use our print features or to download PDF files.